- Home
- LUNG vs SNTI Comparison
LUNG vs SNTI Comparison
Compare LUNG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- SNTI
- Stock Information
- Founded
- LUNG 1995
- SNTI 2016
- Country
- LUNG United States
- SNTI United States
- Employees
- LUNG N/A
- SNTI N/A
- Industry
- LUNG Industrial Specialties
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- SNTI Health Care
- Exchange
- LUNG Nasdaq
- SNTI Nasdaq
- Market Cap
- LUNG 63.6M
- SNTI 53.6M
- IPO Year
- LUNG 2020
- SNTI N/A
- Fundamental
- Price
- LUNG $1.41
- SNTI $1.66
- Analyst Decision
- LUNG Buy
- SNTI Strong Buy
- Analyst Count
- LUNG 7
- SNTI 3
- Target Price
- LUNG $6.81
- SNTI $9.67
- AVG Volume (30 Days)
- LUNG 7.0M
- SNTI 89.7K
- Earning Date
- LUNG 11-12-2025
- SNTI 11-13-2025
- Dividend Yield
- LUNG N/A
- SNTI N/A
- EPS Growth
- LUNG N/A
- SNTI N/A
- EPS
- LUNG N/A
- SNTI N/A
- Revenue
- LUNG $91,664,000.00
- SNTI N/A
- Revenue This Year
- LUNG $10.41
- SNTI N/A
- Revenue Next Year
- LUNG $10.98
- SNTI $150.00
- P/E Ratio
- LUNG N/A
- SNTI N/A
- Revenue Growth
- LUNG 15.59
- SNTI N/A
- 52 Week Low
- LUNG $1.35
- SNTI $1.26
- 52 Week High
- LUNG $9.37
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- LUNG 39.77
- SNTI 45.41
- Support Level
- LUNG $1.65
- SNTI $1.44
- Resistance Level
- LUNG $2.11
- SNTI $1.99
- Average True Range (ATR)
- LUNG 0.17
- SNTI 0.16
- MACD
- LUNG -0.05
- SNTI -0.06
- Stochastic Oscillator
- LUNG 7.24
- SNTI 37.76
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.